Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Recruiting · NCT07593248 · Observational (researchers observe without assigning treatment) · Lead sponsor: AstraZeneca
View the official record on ClinicalTrials.gov →What this trial is about
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosed stage IB-III NSCLC on or prior to the index date;
- Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026
Where it is running
14 locations listed.
- Research Site - Beijing, China
- Research Site - Chengdu, China
- Research Site - Fuzhou, China
- Research Site - Guangzhou, China
- Research Site - Guangzhou, China
- Research Site - Nanchang, China
- Research Site - Shanghai, China
- Research Site - Shenyang, China
- Research Site - Shijiazhuang, China
- Research Site - Tianjin, China
- Research Site - Wuhan, China
- Research Site - Xi'an, China
- Research Site - Xuzhou, China
- Research Site - Zhengzhou, China